UTI Large & Mid Cap Fund
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of large cap and mid cap companies.
Growthvine rating: 3/5 — ranked #15 of 39 in category.
Fund basics
| Category | Equity: Large & Mid Cap |
|---|
| NAV | ₹187.91 (as of 2026-08-21) |
|---|
| AUM | ₹6,407 Cr |
|---|
| Expense ratio | 1.56% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | V Srivatsa |
|---|
| Exit load | 1% for redemption within 364 days |
|---|
Performance & risk
| 5-year annualised return | 14.92% |
|---|
| Sharpe ratio | 0.67 |
|---|
| Standard deviation | 15.05% |
|---|
| Max drawdown | -70.11% |
|---|
| Alpha | 4.01 |
|---|
| Beta | 0.99 |
|---|
Over 5 years, captured 96.2% of NIFTY LargeMidcap 250's upside and 89.0% of its downside.
Market cap allocation
| Large cap | 48.5% |
|---|
| Mid cap | 37.6% |
|---|
| Small cap | 13.9% |
|---|
Concentration
| Top 5 holdings | 19.8% |
|---|
| Top 10 holdings | 32.6% |
|---|
| Total holdings | 71 |
|---|
| Index overlap | 36.9% |
|---|
| Active share | 63.1% |
|---|
Top holdings
- HDFC Bank Ltd. — 5.6%
- ICICI Bank Ltd. — 4.8%
- Reliance Industries Ltd — 3.3%
- Infosys Ltd — 3.1%
- State Bank Of India — 3.0%
- Larsen & Toubro Limited — 2.8%
- Bharti Airtel Ltd. — 2.7%
- ITC Ltd — 2.5%
- Aurobindo Pharma Ltd. — 2.4%
- Aditya Birla Capital Ltd — 2.3%
Top sectors
- Banking & Financial — 19.4%
- Software & Services — 8.7%
- Pharma & Biotech — 8.2%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | -0.1% | Q4 (Bottom) | #30 of 38 |
| 2025 | 7.4% | Q1 (Top) | #9 of 34 |
| 2024 | 27.2% | Q1 (Top) | #7 of 29 |
| 2023 | 34.4% | Q1 (Top) | #4 of 28 |
| 2022 | 4.6% | Q2 | #8 of 28 |